Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Common Equity: 2020-2024

Historic Common Equity for Relay Therapeutics (RLAY) over the last 5 years, with Dec 2024 value amounting to $777.8 million.

  • Relay Therapeutics' Common Equity fell 27.56% to $607.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $607.7 million, marking a year-over-year decrease of 27.56%. This contributed to the annual value of $777.8 million for FY2024, which is 3.43% up from last year.
  • As of FY2024, Relay Therapeutics' Common Equity stood at $777.8 million, which was up 3.43% from $752.0 million recorded in FY2023.
  • In the past 5 years, Relay Therapeutics' Common Equity registered a high of $950.2 million during FY2022, and its lowest value of $752.0 million during FY2023.
  • In the last 3 years, Relay Therapeutics' Common Equity had a median value of $777.8 million in 2024 and averaged $826.7 million.
  • In the last 5 years, Relay Therapeutics' Common Equity grew by 17.62% in 2021 and then declined by 20.86% in 2023.
  • Over the past 5 years, Relay Therapeutics' Common Equity (Yearly) stood at $763.3 million in 2020, then grew by 17.62% to $897.8 million in 2021, then climbed by 5.84% to $950.2 million in 2022, then decreased by 20.86% to $752.0 million in 2023, then rose by 3.43% to $777.8 million in 2024.